SSG
ITRM

Summit Securities Group’s Iterum Therapeutics ITRM Stock Holding History

Summit Securities Group’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,667
Closed -$54K – 667
2020
Q4 		$54K Buy
+3,667
New +$42.9K ﹤0.01% 540

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Summit Securities Group's ITRM Position: Q1 2021 in Review

Summit Securities Group sold out of Iterum Therapeutics (ITRM) in Q1 2021, closing a stake of 3,667 shares — an estimated $54K sold.

Summit Securities Group first reported a position in ITRM in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 50 funds tracked by Wall St. Rank hold ITRM as of Q1 2021.

  • Summit Securities Group reported no remaining Iterum Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Summit Securities Group sold 3,667 Iterum Therapeutics shares in Q1 2021, an estimated $54K.
  • Summit Securities Group first reported a position in Iterum Therapeutics in Q4 2020 and held it in 1 quarter.
  • Summit Securities Group's Iterum Therapeutics position peaked at $54K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2021.

Based on Summit Securities Group's 13F filing for Q1 2021, filed 14 Apr 2021.